Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR [0.03%]
乳腺癌新辅助治疗完全病理缓解(pCR)及其预测因素：EA1181/CompassHER2研究的事后分析
Nadine Tung,Fengmin Zhao,Angela DeMichele et al.
Nadine Tung et al.
Purpose: EA1181 (ClinicalTrials.gov identifier: NCT04266249) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor rec...
Practice Change Following Small Trials in Rare Cancers With Rare Biomarkers [0.03%]
罕见癌症伴罕见生物标志物的小样本试验后的实践改变
Benjamin J Lawrence,Michelle K Wilson,Sanjeev Deva et al.
Benjamin J Lawrence et al.
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3 [0.03%]
驱动基因改变的IV期非小细胞肺癌治疗：ASCO指南（2026.3.3版）
Paul Wheatley-Price,Nofisat Ismaila,Antonio Calles Blanco et al.
Paul Wheatley-Price et al.
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert pa...
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2 [0.03%]
晚期胃食管癌免疫和靶向治疗：ASCO 2026.1.2版循证指南
Manish A Shah,Jacob S Marzalik,Erin B Kennedy et al.
Manish A Shah et al.
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert pa...
Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study [0.03%]
脑肿瘤激光间质热疗的前瞻性多中心分析：LAANTERN研究患者的资料
Eric C Leuthardt,Veronica Chiang,Constantinos G Hadjipanayis et al.
Eric C Leuthardt et al.
Purpose: Laser interstitial thermal therapy is a surgical tool used to ablate brain tumors, radiation necrosis, and epileptic foci. Data from the LAANTERN prospective multicenter registry (ClinicalTrials.gov identifier: N...
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma [0.03%]
用于治疗未接受过治疗的惰性B细胞非霍奇金淋巴瘤的mosunetuzumab与适应性使用polatuzumab vedotin和obinutuzumab
Ryan C Lynch,Christina Poh,Mazyar Shadman et al.
Ryan C Lynch et al.
Purpose: Chemoimmunotherapy has been the standard approach for untreated indolent B-cell lymphoma. We hypothesized that initial use of the CD3/CD20 bispecific mosunetuzumab followed by response-adapted polatuzumab vedotin...
Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions [0.03%]
左帕替尼的安全性，耐受性和抗肿瘤活性：在表皮生长因子受体第20号外显子插入突变的非小细胞肺癌患者中的研究(勘误)
Zofia Piotrowska,Daniel Shao-Weng Tan,Egbert F Smit et al.
Zofia Piotrowska et al.
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma [0.03%]
COMBI-I：Spartalizumab联合Dabrafenib和Trametinib治疗BRAF V600突变型晚期黑色素瘤的长期总生存期分析
Antoni Ribas,Caroline Robert,Dirk Schadendorf et al.
Antoni Ribas et al.
The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n = 265) for BRAF V600-mutant u...
Frantz M Berthaud
Frantz M Berthaud
Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia [0.03%]
复发或难治慢性淋巴细胞白血病的当代疗法
Mathias Castonguay,John F Seymour
Mathias Castonguay
Relapsed or refractory (RR) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presents increasing therapeutic complexity in the era of targeted agents. Frontline use of covalent Bruton tyrosine kinase inhibitors (cBTKis) and...